Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy

Archives of Internal Medicine

Volumn 156, Issue 17, 1996, Pages 1969-1978

  Epstein, Murray ^a,c   Bakris, George ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; BLOOD PRESSURE MONITORING; DIAGNOSTIC ACCURACY; DISEASE CONTROL; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG MIXTURE; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PATIENT COMPLIANCE;

EID: 0029845252     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.17.1969     Document Type: Review

References (88)

1. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens. 1987;3:278-293.
2. Simpson FO, Hodge JV. Evolution of antihypertensive therapy. N Z Med J. 1968;67:270-275.
3. Ausubel H, Levine ML. Treatment of hypertension with Ser-Ap-Es. Curr Ther Clin Exp. 1967;9:29-35.
4. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
5. Elliott WJ. Long-term adherence to 'preferred' vs 'alternative' initial drug monotherapy for hypertension in a tertiary clinic. J Hypertens. 1994; 7(suppl 3):S101. Abstract.
6. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus; 1992:213-230.
7. Bakris GL. Calcium abnormalities and the diabetic, hypertensive patient: implications of renal preservation. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus; 1992:367-388.
8. Ram JL, Standley PR, Sowers JR. Calcium function in vascular smooth muscle and its relationship to hypertension. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus; 1992:29-48.
9. Opie LH. Angiotensin Converting Enzyme Inhibitors: Scientific Basis for Clinical Use. New York, NY: Wiley-Liss Inc; 1992.
10. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med. 1988; 319:1517-1525.
11. Pedersen OL, Christensen NJ, Ramsch KD. Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol. 1980;2:357-366.
12. MacFadyen RJ, Lees KR, Reid JL. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol. 1991;31:1-13.
13. Epstein M, Oster JR. Hypertension: Practical Management. Miami, Fla: Battersea; 1988.
14. Sever P. The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J Hum Hypertens. 1995;9(suppl): S33-S36.
15. Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
16. Attwood S, Bird R, Burch K, et al. Withinpatient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994;12:1053-1060.
17. Ménard J, Bellet M. Calcium antagonists-ACE inhibitors combination therapy: objectives and methodology of clinical development. J Cardiovasc Pharmacol. 1993;21(suppl 2):S49-S54.
18. Weil JV, Chidsey CA. Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation. 1968;37:54-61.
19. Safar ME, Weiss YA, Corvol PL, Menard JE, London GM, Milliez PL. Anti-hypertensive adrenergicblocking agents: effects on sodium balance, the renin-angiotensin system and haemodynamics. Clin Sci. 1975;48:93-95.
20. Lake CR, Ziegler MG, Coleman MD, Kopin IJ. Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients. Clin Pharmacol Ther. 1979;26:428-432.
21. Hui TP, Krakoff LR, Felton K, Yeager K. Diuretic treatment alters clonidine suppression of plasma norepinephrine. Hypertension. 1986;8:272-276.
22. Weber MA, Lopez-Ovejro JA, Drayer JI, Case DB, Laragh JH. Renin reactivity as a determinant of responsiveness to antihypertensive treatment. Arch Intern Med. 1977;137:284-289.
23. Gillmore E, Weil J, Chidsey C. Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. N Engl J Med. 1970;282:521-527.
24. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:2815-2825.
25. Epstein M. Calcium antagonists should continue to be used for first line treatment of hypertension. Arch Intern Med. 1995;155:2150-2156.
26. Epstein M, De Micheli AG. Natriuretic effects of calcium antagonists. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus; 1992:349-366.
27. Campese VM. Salt sensitivity in hypertension. Hypertension. 1994;23:531-550.
28. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension. 1995;26:143-149.
29. Epstein M, Loutzenhiser R. Potential applicability of calcium antagonists as renal protective agents. In: Epstein M, Loutzenhiser R, eds. Calcium Antagonists and the Kidney. Philadelphia, Pa: Hanley & Belfus; 1990:275-294.
30. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med. 1994;154:1430-1431.
31. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461-1468.
32. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J. 1995;130:359-366.
33. Fenichel RR, Lipicky RJ. Combination products as first-line pharmacotherapy. Arch intern Med. 1994;154:1429-1430.
34. Messerli FH. Combination therapy in hypertension. J Hum Hypertens. 1992;6(suppl 2):S19-S21.
35. Isles CG, Walker LM, Beevers GDI, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986;4:141-156.
36. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
37. Frohlich ED. There's good news and not so good news. Hypertension. 1995;25:303-304.
38. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens. 1995;9(suppl 2):S15-S18.
39. Swales JD. Management guidelines for hypertension: is anyone taking notice? J Hum Hypertens. 1995;9(suppl 2):S9-S13.
40. Ménard J, Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens. 1995;9(suppl): S19-S23.
41. Medi-Span Prescription Pricing Guide. Indianapolis, Ind: Medi-Span Inc; 1996.
42. Frohlich ED. The heart in hypertension: a 1991 review. Hypertension. 1991;18(suppl 3):S62-S68.
43. Bakris GL, Frohlich ED. The evolution of antihypertensive therapy: four decades of experience. J Am Coll Cardiol. 1989;14:1595-1608.
44. Arita M, Horinaka S, Frohlich ED. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 1993; 11:951-959.
45. Munter K, Hergenröder S, Jochims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on glomeruloprotection in the stroke prone rat. J Am Soc Nephrol. 1996; 7:681-686.
46. The Enalapril-Hydrochlorothiazide in Essential Hypertension Canadian Working Group. Enalapril and enalapril-hydrochlorothiazide in the treatment of essential hypertension. Clin Ther. 1993; 15:364-373.
47. Vaisse B, Renucci JF, Delage Y, Madonna O, Gressin V, Poggi L. Evaluation of the antihypertensive efficacy of lisinopril and captopril associated with hydrochlorothiazide by ambulatory measurement of arterial pressure. Ann Cardiol Angeiol (Paris). 1993;42:566-572.
48. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Arch Intern Med. 1994;154:737-743.
49. Mayaudon H, Chanudet X, Janin G, Madonna O. Comparison of the efficacy of enalapril+hydrochlorothiazide and captopril+hydrochlorothiazide combinations in mild to moderate arterial hypertension by ambulatory measurement of blood pressure. Ann Cardiol Angeiol (Paris). 1995;44: 235-241.
50. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8: 461-466.
51. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens. 1995;8: 276-281
52. Bakris GL, Wilson DM, Burnett JC Jr. The renal forearm and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986;74:1061-1065.
53. Kincaid-Smith P, Macdonald IM, Hua A, Laver MC, Fang P. Changing concepts in the management of hypertension. Med J Aust. 1975;1:327-332.
54. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens. 1995;13:S15-S19.
55. Safar M, Tzincoca C. Pharmacological basis for a fixed association of hydrochlorothiazide, amiloride hydrochloride and timolol maleate. Semin Hop. 1979;55:1095-1099.
56. Geyskes GG, Stutterheim A, Boer P, Mees EJ. Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone. Eur J Clin Pharmacol. 1975;9:85-90.
57. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182-188.
58. Dahlöf B, Jönsson L, Borgholst O, et al. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Pressure. 1993;2(suppl 1):37-45.
59. Cappuccio FP, Markandu ND, Singer DRJ, MacGregor GA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens. 1993;11:839-848.
60. Singer DRJ, Markandu ND, Shore AC, MacGregor GA. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension. 1987;9:629-633.
61. Anderson A, Morgan T. Interaction of enalapril with sodium restriction, diuretics and slow-channel calcium-blocking drugs. Nephron. 1990; 55(Suppl 1):70-72.
62. Morgan T, Anderson A, Hopper J. Enalapril and nifedipine in essential hypertension: synergism of the hypotensive effects in combination. Clin Exp Hypertens. 1988;10:779-789.
63. Wing LM, Russell AE, Tonkin AL, et al. Monoand combination therapy with telodipine or enalapril in elderly patients with systolic hypertension. Blood Pressure. 1994;3:90-96.
64. ter Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med. 1993; 153:1749-1759.
65. ter Wee P, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
66. Kloke HJ, Huysmans FT, Wetzels JF, Sluiter HE, Klienbloesem CH, Koene RA. Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic failure. Br J Clin Pharmacol. 1989;27(suppl 2): 289S-296S.
67. Hansson L, Himmelmann A. Calcium antagonists in antihypertensive combination therapy. J Cardiovasc Pharmacol. 1991;18(suppl):S76-S80.
68. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic man: importance of therapeutic selection. Kidney Int. 1992; 41:912-919.
69. Gradman AH, for the Enalapril/Felodipine Factorial Study Group. Combination therapy with enalapril/felodipine ER (EF) in essential hypertension: a factorial study. Am J Hypertens. Abstract. In press.
70. Gustafsson D, Grände P-O Borgström P, Lindberg L. Effects of clacium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol. 1988;12:413-422.
71. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
72. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
73. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Infarction Trial II (DAVIT II). Am J Cardiol. 990;66:729-735.
74. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
75. Bakris GL, Williams B. ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens. 1995;13(suppl 2):S95-S101.
76. Kilaru PK, Bakris GL. ACE Inhibition or calcium channel blockade: implications of combination therapy versus single agent. J Cardiovasc Pharmacol. In press.
77. Epstein M. Antihypertensive treatment utilizing a fixed-dose combination of ACE inhibitors and calcium antagonists: emerging perspectives for renal protection. Renal Failure. In press.
78. Wenzel UO, Heimchen U, Schoeppe W, Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension. 1994;23:114-122.
79. Brown S, Walton C, Crawford P, Bakris GL, Comparative renal hemodynamic effects of an ACE inhibitor or calcium antagonist on progression of diabetic nephropathy in the dog. Kidney Int. 1993;43:1210-1218.
80. Gaber L, Walton C, Brown S, Bakris GL. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994;46: 161-169.
81. Lash J, Bakris GL, Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995;10(suppl 9):56-62.
82. Hebert LA, Bain RP, Verme D, et al, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994;46:1688-1693.
83. 2+-antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 1991;14:911-914.
84. Trost BN, Weidman P. Effects of calcium antagonists on glucose homeostasis and serum lipids in nondiabetic and diabetic subjects: a review. J Hypertens. 1987;5:81-104.
85. Atarashi K, Takagi M, Minami M, Kimura Y, Matsuoka H, Sugimoto T. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with noninsulin dependent diabetes mellitus. Blood Pressure. 1992;3(suppl): 130-134.
86. Sugarman A, Kahn T. Calcium channel blockers enhance extrarenal potassium disposal in the rat. Am J Physiol. 1986;250: F695-F701.
87. Solomon R, Dubey A. Diltiazem enhances potassium disposal in subjects with end-stage renal disease. Am J Kidney Dis. 1992;14:420-426.
88. Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine in the treatment of essential hypertensives: a crossover study. J Hypertens. 1987;5(suppl 4):S139-S142.